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Hypereosinophilia: A Diagnostic Dilemma 
Habib Ur Rehman
Abstract
A case of hypereosinophilia is presented. The case illustrates the 
complexity of the diagnostic processes in certain conditions like 
hypereosinophilia.
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Case Report
A 70-year-old man presented with sudden onset weakness 
in his right leg of one day’s duration. He denied headaches, 
chest pains or vomiting. On physical examination the patient 
was afebrile and appeared well. The pulse was 78/minute 
and the blood pressure 128/74 mmHg. No lymphadenopathy 
was found. Examination of the lungs, abdomen, heart, skin, 
musculoskeletal  system  was  normal.  Fundoscopy  did  not 
reveal any abnormality. Neurological examination revealed 
normal strength in upper extremities and left lower extrem-
ity. Strength in the proximal muscles of the right leg was 3/5. 
Reflexes were symmetrical and sensations normal. Cranial 
nerves were intact. 
Past medical history was significant for type 2 diabetes 
mellitus, recurrent idiopathic angioedema, hyperlipidemia, 
rheumatoid arthritis and chronic obstructive lung disease. 
His medication included metformin and glyburide. He trav-
elled to Arizona and Texas every year for 8 years prior to his 
presentation. He was retired and worked in a steel factory. 
Computerized scan (CT) of the brain showed few small 
ill-defined areas of low density in the superior parietal region 
on the left side likely representing infarcts due to embolism. 
Electrocardiogram revealed sinus rhythm and non-specific 
ST-T wave changes. Short bursts of atrial fibrillation were 
demonstrated on the rhythm strip. Ejection fraction was 0.55 
with normal left ventricular systolic function on transthorac-
ic echocardiogram. Transesophageal echocardiography did 
not reveal a cardiac source of emboli. Carotid Doppler ultra-
sound showed minimal amount of plaque within both carotid 
bulbs. There was no hemodynamically significant stenosis 
within the common carotid, internal or external carotid arter-
ies bilaterally.
Haemoglobin    was  108  g/L,  white  blood  cell  14.7  x 
109/L,  neutrophils  3.6  x  109/L,  lymphocyets  1.1  x  109/L, 
monocytes 0.5 x 109/L, eosinophils 9.5 x 109/L, basophils 
0.0 x 109/L. The platelet count was 218 x 109/L. The levels 
of urea nitrogen, creatinine, conjugated and total bilirubin, 
alanine  aminotransferase  and  alkaline  phosphatase  were 
normal. Troponin and brain natriuretic peptide (BNP) values 
were elevated at 2.15 µg/L (< 0.02) and 363.80 ng/L (< 100) 
respectively. Urinanalysis was normal. Two stool samples 
were negative for ova or parasites. A review of the outpatient 
records revealed that eosinophilia was first noticed a year 
prior to his current presentation.
The levels of immunoglobulins were as follows: IgE 
3590 IU/mL (0 - 100), IgG 10.60 g/L (5.52 - 17.24), IgA 2.06 
g/L (0.87 - 3.94), and the IgM 1.12 g/L (0.44 - 2.47). Tests 
for antinuclear antibodies (ANA), antineutrophil cytoplas-
mic antibodies (ANCA) and antimyeloperoxidase antibod-
ies were negative. Complement C3 level was 1.28 g/L (0.74 
- 1.85), complement C4 level was 0.29 g/L (0.16 - 0.44), 
rheumatoid factor level was < 11 IU/mL (0 - 15), and C1 
Inhibitor level was 0.37 g/L (0.21 - 0.39). Immunodiffusion 
test for aspergillus species was negative. Total leukocyte al-
kaline phosphatase score was 78 (20 - 146).
CT  scan  of  the  chest  showed  no  focal  lung  lesions. 
There was quite extensive pleural calcification. There were 
no  pleural  effusions  and  features  suggestive  of  vasculi-
tis. CT scan of the sinuses revealed quite marked mucosal 
thickening of both maxillary sinuses and extensive mucosal 
thickening of ethmoidal and frontal sinuses, consistent with 
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a diagnosis of extensive sinusitis. Pulmonary function tests 
showed normal lung volumes, impaired diffusing capacity 
down to 58% of the predicted normal and mild air flow ob-
struction with FEV1 of 3.5L (FEV1/FVC = 64%) without 
any significant bronchodilator response, diagnosis compat-
ible with chronic obstructive pulmonary disease. Myocardial 
perfusion scan demonstrated partially reversible perfusion 
defects involving the septum and distal inferior wall. Addi-
tional fixed defect was seen involving the majority of the 
apex with an associated wall motion abnormality. Cardiac 
catheterization revealed complete occlusion of the proximal 
left anterior descending (LAD) artery with rich collateral fill-
ing and segmental left ventricular dysfunction but well pre-
served overall left ventricular contractility.
Endomyocardial biopsy was performed. Sections of en-
domyocardial biopsy showed fragments of myocardial tissue 
without significant histopathology. There was no evidence of 
eosinophilic infiltrate. 
Bone marrow aspirate was characterized by diffuse infil-
tration with eosinophils. Eosinophils including eosinophilic 
myelocytes formed 75% of the total cell population. Blast 
count was less than 5%. Erythroid series was normoblas-
tic and myeloid series showed normal maturation. Mega-
karycytes were present in adequate numbers. Plasma cells 
formed less than 5%. No ring sideroblasts were seen. Mar-
row biopsy showed normocellular normoblastic bone mar-
row. Marked eosinophilia, normoblastic erythroid series and 
minimal reticulin fibrosis were other features. Bone marrow 
flow cytometry showed a normal blast population. Cytoge-
netic analysis of the cultured bone marrow revealed a normal 
male karyotype. There were no demonstrable clonal karyo-
typic abnormalities. 
 
Assessment
The patient presented with monoparesis which raises several 
possibilities including cerebrovascular accident, peripheral 
neuropathy, neuromuscular junction disease or a myopathy. 
Both upper motor neuron weakness and lower motor neu-
ron weakness tend to affect distal muscles in symmetric or 
asymmetric fashion. Although hypo or hypertonia, and hypo 
and hyperreflexia would be expected in diseases of the cen-
tral and peripheral nervous system, these abnormalities are 
specific but not sensitive and thus when absent are not help-
ful. Muscle disease should be considered in any patient with 
symmetric weakness of the proximal muscles of the arms and 
leg. Asymmetric leg weakness and the absence of dysphagia 
and neck muscle weakness in our patient make muscle dis-
ease unlikely. Disorders of the neuromuscular junction are 
also unlikely in the absence of ptosis, diplopia and diurnal 
variation in muscle weakness. Lesions of the ipsilateral spi-
nal cord can also cause monoparesis but associated sensory 
abnormalities would be expected. 
History of type 2 diabetes and hyperlipidemia will make 
cerebrovascular disease more likely. However, in view of 
the history of diabetes and frequent travel to Arizona, pe-
ripheral mononeuritis due to diabetes or Lyme disease are 
also possibilities. Rheumatoid arthritis may also be associ-
ated with peripheral neuropathies. Lyme disease is unlikely 
in the absence of other features of Lyme disease like typical 
rash, fatigue, arthritis and cranial nerve palsies. CT findings 
are consistent with an embolic ischemic stroke, however no 
source of the embolism was identified on carotid Doppler 
and transtesophageal echocardiography.
The most notable blood abnormalities are the presence 
of striking eosinophilia, raised levels of IgE and troponin 
levels. Eosinophilia has many causes (Table 1). Troponin rise 
could be due to myocardial damage due to coronary artery 
disease or myocarditis. Total serum IgE levels are elevated 
in a broad array of clinical settings, including infectious, 
oncologic,  inflammatory,  allergic,  and  primary  immuno-
deficiency disorders. Atopy is the most common cause of 
hypergammaglobulinemia-E  worldwide.  Infectious  causes 
include  filariasis,  Schistosomiasis,  Toxocariasis,  Strongy-
loidiasis, Trichurasis, Ascariass, Echinococcus, and hook-
worm infections. These parasitic infections may also cause 
eosinophilia. Nonparasitic infectious causes of elevated IgE 
levels  include  Mycobacterium  tuberculosis,  Epstein-Barr 
virus,cytomegalovirus,  and  human  immunodeficiency  vi-
rus [1]. Gammopathies, Churg-Strauss syndrome (CSS) and 
several primary immunodeficiency disorders are also associ-
ated with elevated IgE levels. Two negative stool samples for 
parasitic diseases and no history of travel to endemic areas 
for parasitic infections make parasitic diseases unlikely. Im-
munoglobulin E-mediated allergy to Aspergillus species can 
cause a brittle form of asthma called allergic bronchopul-
monary aspergillosis (ABPA) [2]. ABPA is characterised by 
asthma, recurrent chest infiltrates on chest radiography, reac-
tive sinusitis, central saccular bronchiectasis, elevated total 
IgE levels and IgG precipitating antibodies to aspergillus fu-
migatus. Although our patient had high serum IgE levels, no 
other features of ABPA were present and immunodiffusion 
test for aspergillus was negative. Churg-Strauss syndrome, a 
small vessel vasculitis, is interesting as it could explain the 
cerebrovascular and myocardial features in our patient and is 
associated with eosinophilia. 
History of recurrent angioedema is intriguing. Angio-
edema is classified into those mediated by bradykinin and 
those dependent on mast cell degranulation. Hereditary and 
acquired forms have been described [3]. Angiotensin-con-
verting  enzyme  (ACE)  inhibitor-induced  angioedema  and 
angioedema associated with C’1 esterase inhibitor depletion 
are well recognized. Idiopathic angioedema is a diagnosis of 
exclusion.
Elevated troponins could be due to either coronary ar-
tery  disease  or  myocarditis.  Myocardial  vasculitis  is  also 
a possibility and presents with signs of heart failure. Non-
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specific ST segment and T wave changes on electrocardio-
gram and global left ventricular dysfunction with small or 
moderate sized pericardial effusion on echocardiography are 
usual findings [4]. It is hard to explain the troponin rise in 
our patient based on coronary anatomy as the appearance of 
a totally occluded LAD coronary artery with rich collateral 
 
Causes of hypereosinophilia
 
Reasons for exclusion in our patient
 
Systemic diseases
Churg-Strauss syndrome
Wegener’s syndrome
Polyarteritis nodosa
Cholesterol crystal embolism
Eosinophilic fasciitis
Rheumatoid arthritis
 
Negative chest X-ray and CT scan
Negative ANCA antibodies, negative ANA, negative 
rheumatoid factor
Eosinophilic pneumonias
Drug-induced pneumonias
Loffler’s syndrome
Allergic bronchopulmonary aspergillosis
Churg-Strauss syndrome
Eosinophilic pneumonia
Normal Chest X-ray and CT results
Although high serum IgE levels, no other features of 
ABPA,negative immunodiffusion test for aspergillus 
Malignancies and immunodeficiencies
Hodgkin lymphoma
Non-Hodgkin lymphoma
Acute and chronic leukaemia
Epithelial cancers
Hyper-IgE syndrome
       Ommen syndrome
Absence of lymphadenopathy clinically and on 
imaging studies, absence of clonal karyotypic 
abnormalities.
Normocellular normoblastic bone marrow
Skin diseases
Bullous pemphigoid
Cutaneous T-cell lymphoma
Systemic mastocytosis
Kimura disease
Well’s disease
Eosinophilic pustular folliculitis
No evidence of skin disease
Drug-induced eosinophilia
Anticonvulsants
Non-steroidal anti-inflammatory drugs
Antimicrobial agents
Sulfa drugs
No history of exposure to drugs known to cause 
eosinophilia
Gastrointestinal diseases
Crohn’s disease
Eosinophilic gastroenteritis
No clinical features (diarrhea, abdominal pain) 
suggestive of gastrointestinal disease
Infections
Helminthic diseases
Human immunodeficiency virus (HIV), Human 
T-lymphocyte virus 1 (HTLV1)
Tuberculosis
Negative stool studies, no history of travel to 
endemic areas
No risk factors for HIV or FTLV1
Normal chest X-ray and CT scan
Table 1. Causes of Hypereosinophilia and Reasons for Exclusion
Adopted from reference [2]
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filling probably represented old lesion. In the setting of non-
specific ST-T wave changes, slight rise in brain natriuretic 
peptide (BNP), and coronary angiographic findings, myo-
carditis would be a more likely cause of the troponin rise. 
Endomyocardial biopsy in our patient was done 2 weeks af-
ter the commencement of high dose steroid therapy. It is pos-
sible that the eosinophilic infiltration of the myocardium had 
regressed by then. The results of normal endomyocardial 
biopsy therefore do not exclude myocarditis in our patient.
 
Differential Diagnosis
The differential diagnosis at this stage would include hyper-
eosinophilic syndrome (HES) and CSS. Eosinophilia and or-
gan damage are two of the overlapping features of HES and 
CSS. It is not always possible to differentiate the two condi-
tions. Asthma, however, is rare in HES but a cardinal feature 
of CSS. Combination of sinus disease and marked eosino-
philia in the context of a multisystem disorder manifested by 
cardiomyopathy and central nervous system involvement is 
suggestive of Churg-Strauss syndrome. The test for ANCA 
is positive in 50 - 70 percent of cases, and a negative test 
thus does not rule out the diagnosis [5]. Absence of severe 
or worsening asthma, no evidence of renal involvement and 
no pulmonary infiltrates in our patient makes CSS unlikely. 
Absence of cytogenetic abnormalities and increase in blast 
cells  and  a  normal  leukocyte  alkaline  phosphatase  score 
makes myeloproliferative variant (M-HES) unlikely in our 
patient. Furthermore hepatomegaly and splenomegaly would 
be expected in M-HES. Flow cytometry did not identify phe-
notypically aberrant subsets of T-cells, making lymphocytic 
variant (L-HES) unlikely, although these abnormalities may 
be discrete and difficult to identify. On the other hand, car-
diac complications, evidenced by elevated troponin-I levels 
in our patient, are more common in M-HES while increased 
serum IgE levels in our patient may point to a diagnosis of 
L-HES.
Our  patient  fits  into  the  category  of  undefined  HES. 
These  patients  may  present  with  cardiac,  pulmonary  or 
neurologic damage. Thromboembolic disease is common. 
Endocardial  damage  and  eosinophilic  myocarditis  is  the 
first manifestation of cardiac disease. Fibrosis of the endo-
cardium results in restrictive cardiomyopathy. A thrombus 
subsequently forms on the damaged endocardium and may 
embolise to the brain causing a stroke or transient ischemic 
attack. A more pronounced eosinophilic count and lack of 
evidence of vasculitis distinguishes it from CSS [6].
Management
  
Patients  presenting  with  potentially  life-threatening  com-
plications,  including  cardiac  or  neurologic  involvement, 
and marked eosinophilia should be treated empirically with 
high-dose corticosteroids to prevent progression of end or-
gan damage, particularly when infectious causes have been 
excluded. End organ damage and high eosinophil counts in 
our patient warranted a course of steroid treatment. Treat-
ment with 60 mg prednisone orally was initiated, with rapid 
improvement in symptoms and reduction of peripheral eo-
sinophilia to normal range. In patients with aggressive dis-
ease unresponsive to high-dose corticosteroids, addition of 
Imatinib  therapy  should  be  considered  early.  Vincristine 
should be reserved for patients with rapidly progressive, life-
threatening disease unresponsive to high-dose steroids and 
imatinib therapy [7].
The patient was gradually weaned off prednisone over 
the next 6 months but required a titration up of the predni-
sone dose to 40mg daily when the dose was reduced to 5mg 
daily. This resulted in prompt resolution of eosinophilia. He 
remains asymptomatic with a normal eosinophil count 1 year 
later and is being followed up closely.
Discussion
This case illustrates diagnostic processes involved in a very 
complex and challenging set of problems. Diagnostic pro-
cess involves both analytical and non-analytical analysis. It 
also involves causal reasoning to pin-point the role of fac-
tors responsible for the condition of the patient at any time 
during the course of disease [8]. Non-analytic reasoning is 
pattern recognition but is usually not useful in complex cases 
such as presented. Analytic reasoning is the primary strategy 
when a case is complex or when the clinical findings are un-
usual [9]. Experience is essential for non-analytic thinking 
whilst a wide knowledge base and critical and lateral think-
ing form the bases for analytic thinking. 
Eosinophilia,  cerebrovascular  disease  and  myocardial 
damage were the essential “important” features of the case 
discussed and a differential diagnosis was based on these 
important positive findings. The wide differential diagnosis 
was gradually narrowed as more information became avail-
able. This was based on both positive findings such as CT 
results of the brain but also importantly on negative findings 
such as chest CT results, stool tests for ova and parasites and 
cytogenetic analysis of bone marrow. 
Hypereosinophilic syndromes (HES) are a rare group 
of heterogeneous disorders characterized by persistent eo-
sinophilia  defined  as  >1500/μL  lasting  >  6  months  with 
evidence of eosinophil induced organ dysfunction in which 
other known causes of eosinophilia has been excluded. Hy-
pereosinophilic Diseases Working Group has established 6 
separate categories of hypereosinophilic diseases; myelopro-
liferative variant (M-HES), lymphocytic variant (L-HES), fa-
milial eosinophilia, undefined, overlap, and associated [10]. 
Diagnosis of HES requires three criteria to be met. First, re-
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active causes of eosinophilia must be excluded to diagnose 
HES (Table 1). Second, the criteria of eosinophil-mediated 
tissue damage must be satisfied. Third, molecular basis of 
eosinophilia should be determined. This includes peripheral 
blood molecular genetic analysis for (FIP1L1-PDGFRA) fu-
sion and bone marrow cytogenetic analysis. 
Myeloproliferative variant (M-HES) of HES is due to 
genetic abnormalities leading to clonal expansion of the my-
eloid linage. Lymphocytic variant (L-HES) is due to over-
production of eosinophilopoietic cytokines by abnormal cir-
culating T-cell subsets [11]. 
Clinical  manifestations  of  HES  may  involve  heart, 
skin, lung, nervous system and gastrointestinal tract. Car-
diac involvement may manifest as myocarditis, endocardial 
thrombi or endomyocardial fibrosis causing fatal restrictive 
cardiomyopathy. Electrocardiogram may show non-specific 
and diffuse T-wave inversion. Echocardiogram and cardiac 
magnetic resonance imaging (MRI) are sensitive modalities 
for the detection of endomyocardial fibrosis and intracardiac 
thrombi. Endomyocardial biopsy is the gold standard for di-
agnosis of endomyocardial fibrosis.
Pulmonary symptoms may include dry cough, dyspnoea, 
and chest discomfort. Radiological findings are non-specific 
and may include infiltrates or diffuse interstitial pneumo-
nia and fibrosis. Cutaneous manifestations include pruritis, 
erythematous  rash,  papules,  nodules,  eczema-like  lesions, 
and urticaria-like eruptions. Mucosal ulcerations are more 
common in M-HES, whereas angioedema with elevated IgE 
levels is suggestive of L-HES variant. Vascular manifesta-
tions may be due to small vessel vasculitis or large vessel 
involvement  causing  digital  necrosis,  thrombophlebitis  or 
Budd-Chiari syndrome.
Nervous system manifestations include diffuse encepha-
lopathy, transient ischemic episodes, stroke, and peripheral 
sensory  neuropathies. Abdominal  pain,  diarrhoea,  ascites, 
pancreatitis and cholangitis may be manifestations of gas-
trointestinal tract involvement. Hepatomegaly and spleno-
megaly are common in M-HES.
The familial form of HES is a very rare entity. Auto-
somal dominant pattern has been described in one kindred 
[12]. Cases of unexplained eosinophilia that do not meet the 
other classification criteria may be classed as undefined. This 
category includes a benign variant with no evidence of organ 
dysfunction; a complex variant with organ dysfunction but 
does not meet criteria for myeloproliferative or lymphocytic 
variant; and a cyclical variant with recurrent angioedema and 
eosinophilia. 
Overlap category includes cases where tissue-specific 
eosinophilia is restricted to specific organs. This category 
includes eosinophilic esophagitis, eosinophilic gastroenteri-
tis, eosinophilic pneumonia, and eosinophilia-myalgia syn-
drome. Associated category is association of eosinophilia 
with  other  defined  diagnosis  such  as  Churg-Strauss  syn-
drome, systemic mastocytosis, sarcoidosis, human immuno-
deficiency virus (HIV), or inflammatory bowel disease. 
Our patient did not fit into either overlap or associated 
categories. Gleich’s syndrome is characterised by eosino-
philia accompanied by recurrent episodes of angioedema, 
urticaria, pruritis, fever, weight gain, elevated serum IgM, 
oliguria, and eosinophilia. Our patient did not have these fea-
tures except episodic angioedema and eosinophilia.
Corticosteroids remain the first line treatment for most 
patients with HES, with the exception of PDGFRA-asso-
ciated HES. The most appropriate initial dose and duration 
of treatment have not been studied but a dose of prednisone 
≥40mg has been suggested. Most patients respond to this 
dose. The dose should than be tapered very slowly to the 
lowest possible dose whilst monitoring the eosinophil count 
closely. Evaluation of bone density and adjunctive treatment 
to prevent bone loss is required in those requiring long-term 
steroid  treatment  [9].  Hydoxyurea,  interferon-α,  imatinib, 
and vincristine have been used in steroid-refractory cases. 
Preliminary results with monoclonal antibody therapy have 
been encouraging and have resulted in prolonged remission 
rates in the majority of patients [13, 14]. Imatinib mesyl-
ate is a tyrosine kinase inhibitor and has activity against the 
fusion kinase FIP1L1/PDGFRA, responsible for PDGFRA-
associated HES. Imatinib mesylate is the first line treatment 
in patients with myeloproliferative-HES and results in rapid 
normalization of eosinophil count and clinical features. Al-
logenic bone marrow transplantation is reserved for patients 
with FIP1L1/PDGFRA-positive disease who are either resis-
tant or intolerant to imatinib therapy [9].
Hypereosinophilic syndrome includes a variety of dis-
orders without any identifiable cause resulting in a wide va-
riety of clinical manifestations with considerable overlap in 
clinical and laboratory features. A definitive diagnosis can 
be difficult because of these overlapping clinical and labora-
tory features and is further hampered by the fact that these 
disorders have to be distinguished from other entities associ-
ated with eosinophilia and end organ damage. A diagnosis of 
undefined variant of HES was eventually made by a process 
of analytic reasoning.
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